

09PH
55273



**Studies on the
Evidence Base in Support of
Digoxin Therapeutic Drug Monitoring**

**Sepehr Shakib
MBBS (Hons), FRACP**

Department of Clinical and Experimental Pharmacology
University of Adelaide

Submitted in fulfilment of the requirements for the degree of
Doctorate of Philosophy in December 2005

Table of Contents

TABLE OF CONTENTS	ii
LIST OF TABLES	vi
LIST OF FIGURES	ix
ABSTRACT	xii
DECLARATION	xiv
ACKNOWLEDGEMENTS	xv
DEDICATION	xvi
CHAPTER 1: INTRODUCTION	1
1.1 Overview of Therapeutic Drug Monitoring	1
1.1.1 Principles of Appropriateness of TDM	3
1.1.2 History of Development of TDM.....	5
1.1.3 Impact of TDM on Clinical Practice	7
1.2 Principles of Evidence Based Medicine.....	8
1.2.1 Levels of Evidence	9
1.3 Application of EBM Principles to TDM.....	11
1.3.1 Evidence Base for Therapeutic Drug Monitoring of Different Drug Classes.....	20
1.4 Therapeutic Drug Monitoring of Digoxin	26
1.4.1 Clinical Pharmacology of Digoxin	26
1.4.2 Development of Digoxin TDM.....	27
1.4.3 Evaluation of Digoxin TDM	31
1.5 Summary and Aims of Thesis	43
CHAPTER 2.: RANDOMISED CONTROLLED TRIAL OF DIGOXIN THERAPEUTIC MONITORING - PILOT STUDY	45
2.1 Introduction.....	45
2.2 Methods.....	46
2.3 Results.....	58
2.4 Discussion	61
2.5 Conclusion.....	65

CHAPTER 3: UTILITY OF DIGOXIN ASSAYS IN THE DIAGNOSIS OF DIGOXIN TOXICITY	66
3.1 Introduction.....	66
3.2 Methods.....	70
3.2.1 Patient Data Collection	70
3.2.2 Computerised Form	71
3.2.2 Digoxin Concentration Determination.....	75
3.2.4 Statistical Analysis	75
3.3 Results.....	76
3.4 Discussion	84
3.5 Conclusion.....	91
CHAPTER 4: THE USEFULNESS OF ROUTINE DIGOXIN ASSAYS ON ADMISSION TO MEDICAL UNITS	92
4.1 Introduction.....	92
4.2 Methods.....	93
4.2.1 Data Collection Tool.....	94
4.2.2 Digoxin Concentration Determination.....	97
4.2.3 Statistical Analysis	98
4.3 Results.....	98
4.4 Discussion	112
4.5 Conclusion.....	127
CHAPTER 5: SYSTEMATIC SURVEY OF SYMPTOMS OF DIGOXIN TOXICITY AND CORRELATION WITH SERUM DIGOXIN CONCENTRATIONS IN HOSPITAL INPATIENTS	130
5.1 Introduction.....	130
5.2 Methods.....	132
5.2.1 Patients	133
5.2.2 Questionnaire.....	134
5.2.3 Colour Vision Testing.....	136
5.2.4 Factors Altering Sensitivity to Digoxin	141
5.2.5 Digoxin Concentration Determination.....	143
5.2.6 Statistical Analysis	143

5.3 Results.....	145
5.3.1 Patient Characteristics	145
5.3.2 Questionnaire Results.....	149
5.3.3 Prevalence of Symptoms at Increasing SDCs	156
5.3.4 Influence of Factors Which May Alter Sensitivity to Digoxin	162
5.3.4.1 Anorexia	162
5.3.4.2 Nausea.....	164
5.3.4.3 Vomiting	165
5.3.4.4 Tiredness	166
5.4 Discussion	166
5.5 Conclusion.....	180
CHAPTER 6: ELECTROCARDIOGRAPHIC CHARACTERISATION OF DIGOXIN TOXICITY .	181
6.1 Introduction.....	181
6.2 Methods.....	184
6.2.1 Patient Selection and Data Collection	184
6.2.2 Digoxin Concentration Determination.....	185
6.2.3 Electrocardiographic Assessments	185
6.2.4 Determination of Toxic Rhythms	189
6.2.5 Statistical Analysis	189
6.3 Results.....	190
6.3.1 Patient Characteristics	190
6.3.2 Rhythm Analysis	191
6.3.3 Analysis of Premature Ventricular Complexes.....	194
6.3.4 Analysis of ST Segment Sagging	195
6.3.5 Analysis of Quantitative Data.....	195
6.3.6 Factors Altering Sensitivity to Serum Digoxin Concentration.....	206
6.4 Discussion	208
6.4.1 Analysis of Quantitative Variables	211
6.4.2 Factors Altering Sensitivity to Serum Digoxin Concentration.....	216
6.5 Conclusion.....	218

CHAPTER 7: CONCLUSION AND FUTURE DIRECTIONS	220
7.1 Overview of Thesis.....	220
7.2 Conclusions.....	220
7.2.1 Randomised Controlled Trial of Digoxin Therapeutic Monitoring - Pilot Study	220
7.2.2 Utility of Digoxin Assays In The Diagnosis Of Digoxin Toxicity.....	221
7.2.3 The Usefulness of Routine Digoxin Assays on Admission to Medical Units.....	223
7.2.4 Systematic Survey of Symptoms of Digoxin Toxicity and Correlation with Serum Digoxin Concentrations in Hospital Inpatients	225
7.2.5 Electrocardiographic Characterisation of Digoxin Toxicity.....	226
7.3 Future directions.....	229
APPENDIX A: EXAMPLES OF LEVELS OF EVIDENCE HIERARCHY USED BY DIFFERENT INSTITUTIONS	231
APPENDIX B: ETHICS COMMITTEE PROTOCOLS	234
REFERENCES:	272

Abstract

Despite being available for over 3 decades, there is a dearth of high level evidence for the benefit of digoxin therapeutic drug monitoring (TDM) on clinical endpoints. A pilot randomised controlled trial of digoxin TDM was conducted in hospital inpatients. Clinical endpoints were difficult to collect without considerable additional resources. The main barrier to performing a full-scale randomised trial of digoxin TDM would be the required sample size, which would be over 1,500 patients for a hard endpoint such as incidence of toxicity.

The benefit of the knowledge of the serum digoxin concentration (SDC) in determining the likelihood of digoxin toxicity was assessed by presenting blinded clinicians clinical and SDC data using a computerised interface. The main benefit of the knowledge of the SDC was to reduce the percentage of patients classified as “possibly toxic”, and to increase the agreement between clinicians. Those who were assessed as being more likely to be toxic after the knowledge of the SDC were also more likely to have symptoms of digoxin toxicity.

The impact of determining the SDC on all patients prescribed digoxin admitted to medical units of a tertiary referral hospital was assessed. Approximately one fifth of all patients had their management altered as a result of the knowledge of the SDC. In patients, in whom there was no indication for a digoxin assay, and the intended management was to “continue the same”, approximately one tenth had a change in their management as a result of the knowledge of the SDC. It is possible to predict, on clinical grounds, patients who are more likely to have such an alteration, and in whom the test has greater clinical utility.

A systematic survey of symptoms and electrocardiographic changes associated with digoxin toxicity was conducted in hospital inpatients. The only symptoms found to be significantly associated with higher SDCs were anorexia, nausea, vomiting, fatigue, and subjective changes in colour vision. Although some colour vision tests can also identify patients with high SDCs, the only symptoms which are clinically useful for the assessment of toxicity, in current clinical practice, are assessment of digoxin's emetic effects. The predominant effect of increasing SDCs on the electrocardiogram was increasing prevalence and severity of bradycardic rhythms, without an increase in automaticity.

An increase in the prevalence of cardiac and non-cardiac manifestations of digoxin toxicity became clear at approximately 1.0 ng/ml which is at the lower end of the currently quoted therapeutic range. In light of these findings the current therapeutic range for digoxin should be revised.